com

According to the AOA, 20. Optometry school consists of four years of post-graduate,
doctoral study concentrating on both the eye and systemic health .S. She joined OccuLogix from Boehringer Ingelheim, where she worked for the past 9 years, most recently as Director of the National Medicine Department., OccuLogix's Vice President, Clinical Affairs, who will be leaving the company to pursue other opportunities. Dumencu succeeds John Y. OccuLogix's common shares trade on the NASDAQ National Market under the symbol 'RHEO' and on the Toronto Stock Exchange under the symbol 'RHE'. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. We do not undertake to update any forward-looking statements.

For sites about personal experiences dealing with blindness.

blind bombing

Expanding OccuLogix's ophthalmic pipeline beyond the RHEO procedure for Dry AMD was already a longer-term corporate objective. Based at the world renowned Boston University Photonics Center, SOLX is a privately held company that has developed a next generation system that represents a paradigm shift in the way glaucoma is currently treated.0 to 13 . At first, peripheral vision is lost. In the United States, approximately 2.

rop kenya

Food and Drug Administration ("FDA") in the second quarter to discuss what impact the MIRA-1 study results and the modified per-protocol analysis will have on its application to market its RHEO System in the United States. Westing helped establish the thought leader development program for Genentech's newly launched Lucentis franchise and he served as a member of Genentech's ophthalmology commercial strategy team.

bomer blindness

8
million baby boomers will celebrate their 60th birthday, age-related eye
diseases are becoming increasingly important health issues, according to the
American Optometric Association. She has served on several committees in the National Science and Engineering Research Committee of Canada and has an appointment at the University of Toronto as lecturer. in Muscle Physiology at The Karolinska Institute, Stockholm, Sweden.2 million people age 40 and older have glaucoma, and of these, as many as 120,000 are blind due the disease.

Forward Looking Statements

This press release may contain forward-looking statements.

nairobi survivor

"Many people don't understand that even though their vision may be clear,
exams can uncover changes in the eye caused by high blood pressure, diabetes,
retinal disorders and glaucoma," said Dr. Dr . "I'm also excited to welcome Drs. The number of Americans with glaucoma is estimated to increase to 3.rheo.

toward eyesight

LOUIS, In a year where an estimated 2.D.

prematurity visually

"But being better informed about health risks,
improved technology and treatment options has not necessarily translated into
including regular eye examinations into their health care routine. commercial launch of its RHEO System, the Company has accelerated its diversification plans, focusing on age-related eye diseases like AMD and glaucoma as they are expected to be the fastest growing segments of eye care over the next 10 years. Both of the components of SOLX 's DeepLight System have received CE approval from the European Agency for the Evaluation of Medicinal Products and are currently the subject of two randomized, multi-center studies in the United States .

Steve Westing, Ph. from May 1990.P.

Worldwide, it is estimated that approximately 67 million people have visual impairment from glaucoma, with 6.3 million by the year 2020

About OccuLogix, Inc. These statements are only predictions based on our current expectations and projections about future events.

bomer bombing

Cyberkinetics, a leader in neurotechnology, an emerging field
driven by advances in neuroscience, computer science, and engineering,
is focused on treating diseases and disorders of the nervous system.cyberkineticsinc.
"Age-related eye diseases do not have to lead to vision loss or
blindness," Dr."

About the American Optometric Association (AOA):
The American Optometric Association represents more than 34,000 doctors of
optometry, optometry students and paraoptometric assistants and technicians. Like our RHEO system, the DeepLight System has the potential to represent a significant benefit for patients, as well as a tremendous market opportunity for OccuLogix.

About Glaucoma

Glaucoma is a group of age-related eye diseases characterized by elevated intraocular pressure, which cause optic nerve damage and subsequent loss of eyesight.

survivor impaired

, American Optometric Association Information
and Data Committee chair. In addition to providing
eye and vision care, optometrists play a major role in a patient's overall
health and well-being by detecting systemic diseases such as diabetes and
hypertension.com (healthcare professionals, patients and caregivers ).

blinded bomer

(OTCBB:CYKN) announced today that
Timothy R. While the Company cannot predict what the FDA will require for approval, management believes that it is more likely than not that further study will be required due to the fact that the modified per-protocol population comprised 115 complete data sets while the Company had been required to obtain a minimum of 150 complete data sets., has recently joined OccuLogix as Vice President, Clinical Research. Choudry has an accomplished history in global drug development and clinical trial management. Dumencu has served as OccuLogix's V.

mchugh visually

cyberkineticsinc. More information is available at
www. In addition
to their formal training, doctors of optometry must undergo annual continuing
education to stay current on the latest standards of care. While financial terms of the transaction were not disclosed, OccuLogix will provide SOLX with a $2 million bridge loan and has advised that it expects substantially all of the purchase price of SOLX to be paid in OccuLogix stock."

Management Changes

In connection with its new strategic direction, OccuLogix has made a number of structural and management changes designed to both support the continued development of its existing Dry AMD program and to execute on its accelerated diversification strategy within ophthalmology.D. Choudry worked at Ciba-Geigy (now Novartis Corporation) where she held increasingly senior roles in drug development and clinical trial management. Dr. In that role, Dr. Choudry and Westing to the Company.

bomer blindness

"
The National Eye Institute estimates that over the next 30 years, the
current number of blind or visually impaired Americans will double because of
aging baby boomers. (NASDAQ: RHEO)(TSX:RHE) today provided a strategic update and announced its planned acquisition of SOLX, Inc. In light of the possible delay in the U. The DeepLight Glaucoma Treatment System ("DeepLight System") includes the DeepLight 790 Titanium Sapphire Laser and the novel DeepLight Gold Micro-Shunt, which can be used separately or together to provide patients with multiple options for maximum intraocular pressure ("IOP") management."

Doug Adams, SOLX's President and CEO, commented "SOLX and OccuLogix together will provide new hope for the patients suffering from these potentially blinding eye diseases. From March 1993 to August 1996, Dr .

There are two types of AMD - "dry", or non-exudative, and "wet", or exudative.

survivor astrid

Cyberkinetics Neurotechnology Systems to Participate in the 7th Annual BIO CEO + Investor Conference

An archived recording
of the presentation will be available at the same location.

On March 9, 2006, OccuLogix announced positive results from the modified per-protocol analysis of MIRA-1, the Company's recently completed pivotal (phase III) clinical trial using its RHEO System to treat the dry form of age-related macular degeneration ("Dry AMD"). Choudry will be assuming the responsibilities of Irving Siegel, M ., has been appointed OccuLogix's Vice President, Medical and Scientific Development, effective April 10, 2006. Before joining Genentech in May 1996, Dr.

retinopathy visually

In 3,500 of those communities they are the only eye doctors. For more
information, visit http://www. of Boston, Massachusetts. Choudry earned her Ph. Mr.

recovering toward

Edlow said.
American Optometric Association doctors of optometry are highly qualified ,
trained doctors on the frontline of eye and vision care who examine, diagnose,
treat and manage diseases and disorders of the eye.S. in Clinical Pharmacology at the Royal Postgraduate Medical School in London, England and has done extensive post-graduate research and publishing in both pharmacology and medicine. Caloz who will be leaving the company to pursue other opportunities.

rop nairobi

Pharmaceutical Writers/Business Editors/Health/Medical
Writers/Biotech Writers
7th Annual BIO CEO + Investor Conference
BIOWIRE2K

FOXBOROUGH, Mass----Cyberkinetics
Neurotechnology Systems, Inc.
Cyberkinetics ' first product, the BrainGate(TM) Neural Interface
System, is designed to give severely paralyzed individuals a
long-term, direct brain-computer interface for the purpose of
communication and control of a computer and other devices.

Nozhat Choudry, Ph. Dr.D. Dr. Dumencu, CA, has been appointed as the company's interim Chief Financial Officer and Treasurer, effective April 10, 2006.

Mr.

OccuLogix is a health care company that brings innovative and evidenced-based medical therapies to market.

Based at the Boston University Photonics Center in Boston, Massachusetts, SOLX is a privately held company developing new approaches to glaucoma treatment. Actual events or results may differ materially.

programmer survivor

Save Your Vision Month Promotes Regular Eye Exams

ST.
"Today's 60-year-olds are more health conscious than 60-year-olds 20 years
ago," said Richard C. Edlow. "Since there are more
treatment and rehabilitation options than ever before, early detection is all
the more critical.

OccuLogix has initiated its expansion into the glaucoma space by signing a Letter of Intent to acquire SOLX, Inc. SOLX expects to obtain 510K approval to market both components of the DeepLight System in the United States before the end of 2007. Dr. Westing worked at Loredan Biomedical, Inc. Westing earned his Ph."

About AMD

Age-related macular degeneration causes damage to the macula - the light-sensitive cells at the center of the retina at the back of the eye.

blindness embassy

"I deeply appreciate all of the hard work and valuable insights that John Caloz and Irv Siegel provided and wish them both well in their future endeavors," said Vamvakas. Visit us on the internet at www.SOLX.

programmer mchugh

About Cyberkinetics Neurotechnology Systems, Inc. Cyberkinetics is headquartered
in Foxborough, Massachusetts and conducts engineering and research in
Salt Lake City, Utah.

Optometrists Anticipate 'Boom' in Eye Diseases as Baby Boomers Turn 60

org . There, he held increasingly senior roles in product sales and development.7 million suffering from blindness.com. You should not place undue reliance on these statements.

rop blindness

Surgenor, Chief Executive Officer of Cyberkinetics, will
present at the 7th Annual BIO CEO + Investor Conference at 12:00 PM
(ET) on Thursday, February 24, 2005 at the Waldorf Astoria Hotel in
New York.
Interested parties can access a live audio web cast of the
presentation through a link on the Investor Relations page of the
company's website at www . Cyberkinetics'
intellectual property features key technologies licensed from Brown
University , the Massachusetts Institute of Technology, Emory
University, and the University of Utah.D.
Prior to optometry school, optometrists undergo three to four years of
undergraduate study that typically culminates in a bachelor's degree with
extensive, required coursework in areas such as advanced health, science and
mathematics.

PRESS RELEASE OccuLogix Expands Focus on Age-Related Eye Diseases

Westing will be primarily responsible for identifying and developing relationships with key opinion leaders within ophthalmology, and for managing the recruitment of trial sites and patients to participate in OccuLogix sponsored clinical studies. I look forward to their input as we work toward building a strong leadership position for OccuLogix within the ophthalmic device space. Currently, there is no FDA approved treatment for Dry AMD.

prematurity eyesight

OccuLogix, Inc.

Elias Vamvakas, OccuLogix 's Chairman and CEO, commented "We're excited to be expanding our focus beyond Dry AMD by entering the fast-growing glaucoma space. Paralleling our own novel device approach to the treatment of age-related eye diseases, we believe that SOLX's product portfolio represents the perfect fit for OccuLogix's development and commercialization capabilities.

Mr. Finance since June 2005 and was previously OccuLogix 's Chief Financial Officer and Treasurer from September 2003.5 million people in the United States, representing approximately 85% to 90% of all AMD cases in the country.

lenny blindness

5 million people age 60 and over
have cataracts, a leading cause of poor vision in the United States. OccuLogix plans on meeting with the U.D. (NYSE: DNA), where he most recently served as Associate Director - Advisory and Thought Leader Services. William (Bill) G. The macula is responsible for our ability to see with enough detail to read , drive, watch television and perform other activities that require focused, straight-ahead vision, as well as providing information that allows us to perceive colors; thus, allowing one to maintain independence in daily activities. If glaucoma is not treated, vision loss may continue, leading to total blindness over time. SOLX's DeepLight Glaucoma Treatment System is being developed to provide physicians with new tools to reduce intraocular pressure. More information can be found online at www.

programmer inspiring

com.
Optometrists provide more than two-thirds of all primary eye care in the
United States and serve patients in nearly 6,500 communities across the
country. Together we will continue to focus our commitment and resources in changing the very paradigm by which physicians view and treat age-related eye diseases. Dr.D. Dry AMD, the most common form of the disease, currently afflicts approximately 13.

blinded visually

Patients
are currently being enrolled into a pilot clinical trial to test the
BrainGate system's safety and effectiveness . As part of national Save Your Vision Month
in March, the AOA is reminding Americans 60 and older that early detection
through a comprehensive eye exam can prevent or slow vision loss due to
cataracts and other age-related eye diseases such as macular degeneration,
glaucoma and diabetic retinopathy . Edlow, O.aoa.

OccuLogix's Planned Acquisition of SOLX, Inc. Westing is joining OccuLogix from Genentech, Inc.

prematurity rop

"Some of these have no symptoms in the early
stages, which is when it is most critical to help slow the progression of
vision loss."
A comprehensive eye examination provides doctors of optometry with
information about the health of the eyes, and also offers indications about
diseases that affect the whole body, like diabetes and hypertension.

About SOLX, Inc. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian regulatory authorities , including our Registration Statement on Form S-1.

motivational astrid

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)